EntreMed appoints interim CEO
This article was originally published in Scrip
Executive Summary
The clinical-stage cancer company has appointed Dr Ken Ren as interim CEO, effective 2 April 2012. Dr Ren has years of experience in conducting global trials for multi-national pharmaceutical and biotech companies, and was also the founder and key manager of several private companies operating in the US and China in pharmaceutical development and services. The new appointment comes just months after the company announced that it had appointed Dr Wei-Wu He executive chair, and Dr Tak Mak to its board of directors.